20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Abbott Laboratories (ABT) operates in the Health Care Equipment industry and is headquartered in Abbott Park, United States with about 122,000 employees. Its market capitalization is roughly $180 billion. In the fiscal year ended 2025-12-31, ABT reported $44.3B in revenue and $6.5B in net income.
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
Interactive charts & full statements → Open the ABT valuation workbench →
| Income statement | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $45.1B | $44.3B | $42.0B | $40.1B | $43.7B | $43.1B | $34.6B | $31.9B | $30.6B | $27.4B | $20.9B | $20.4B | $20.2B | $21.8B | $39.9B | $38.9B | $35.2B | $30.8B | $29.5B | $25.9B | $22.5B |
| Gross Profit | $25.4B | $24.6B | $21.3B | $20.0B | $22.3B | $23.2B | $17.4B | $16.7B | $15.8B | $13.1B | $11.2B | $11.0B | $10.5B | $9.9B | $10.9B | $23.4B | $20.6B | $17.6B | $17.0B | $14.6B | $12.8B |
| Gross Margin % | 56.4% | 55.5% | 50.8% | 50.0% | 51.1% | 53.9% | 50.2% | 52.3% | 51.7% | 47.7% | 53.9% | 53.7% | 51.8% | 45.1% | 27.2% | 60.3% | 58.6% | 57.3% | 57.7% | 56.3% | 57.1% |
| Operating Income (EBIT) | $8.2B | $8.0B | $6.8B | $6.4B | $8.4B | $9.2B | $5.3B | $4.6B | $3.8B | $2.0B | $3.2B | $2.9B | $2.9B | $2.1B | $2.0B | $6.8B | $7.1B | $6.6B | $6.1B | $4.9B | $4.3B |
| Operating Margin % | 18.2% | 18.2% | 16.3% | 16.0% | 19.2% | 21.4% | 15.3% | 14.4% | 12.6% | 7.2% | 15.6% | 14.4% | 14.4% | 9.8% | 5.0% | 17.6% | 20.1% | 21.4% | 20.6% | 19.1% | 19.3% |
| Net Income | $6.3B | $6.5B | $13.4B | $5.7B | $6.9B | $7.1B | $4.5B | $3.7B | $2.4B | $477M | $1.4B | $4.4B | $2.3B | $2.6B | $6.0B | $4.7B | $4.6B | $5.7B | $4.9B | $3.6B | $1.7B |
| Net Margin % | 13.9% | 14.7% | 31.9% | 14.3% | 15.9% | 16.4% | 13.0% | 11.6% | 7.7% | 1.7% | 6.7% | 21.7% | 11.3% | 11.8% | 14.9% | 12.2% | 13.2% | 18.7% | 16.5% | 13.9% | 7.6% |
| EBITDA | $11.2B | $11.6B | $10.8B | $10.6B | $11.9B | $12.2B | $9.0B | $7.9B | $6.9B | $6.1B | $3.1B | $4.8B | $4.2B | $3.6B | $3.5B | $9.3B | $9.1B | $9.5B | $8.2B | $6.9B | $4.3B |
| Earnings Per Share (EPS) | $3.59 | $3.73 | $7.67 | $3.27 | $3.93 | $3.95 | $2.52 | $2.07 | $1.34 | $0.27 | $0.94 | $2.94 | $1.50 | $1.64 | $3.75 | $3.01 | $2.97 | $3.70 | $3.13 | $2.31 | $1.12 |
| Shares Outstanding (M) | 1,747M | 1,747M | 1,748M | 1,749M | 1,764M | 1,789M | 1,786M | 1,781M | 1,770M | 1,749M | 1,483M | 1,506M | 1,527M | 1,574M | 1,592M | 1,570M | 1,556M | 1,555M | 1,561M | 1,560M | 1,537M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $11.2B | $11.5B | $11.4B | $11.1B | $10.4B | $11.0B | $10.6B | $10.4B |
| Gross Profit | $6.3B | $6.5B | $6.3B | $6.3B | $5.4B | $5.6B | $5.4B | $5.3B |
| Gross Margin % | 56.3% | 57.0% | 55.8% | 56.4% | 52.6% | 51.0% | 51.0% | 51.1% |
| Operating Income (EBIT) | $1.8B | $2.3B | $2.1B | $2.1B | $1.7B | $2.0B | $1.8B | $1.7B |
| Operating Margin % | 16.5% | 19.6% | 18.1% | 18.4% | 16.3% | 18.1% | 17.1% | 16.2% |
| Net Income | $1.1B | $1.8B | $1.6B | $1.8B | $1.3B | $9.2B | $1.6B | $1.3B |
| Net Margin % | 9.7% | 15.5% | 14.5% | 16.0% | 12.8% | 84.1% | 15.5% | 12.6% |
| EBITDA | $2.2B | $2.8B | $3.1B | $3.0B | $2.7B | $3.0B | $2.9B | $2.6B |
| Earnings Per Share (EPS) | $0.62 | $1.02 | $0.94 | $1.02 | $0.76 | $5.29 | $0.94 | $0.74 |
| Shares Outstanding (M) | 1,747M | 1,747M | 1,749M | 1,751M | 1,747M | 1,746M | 1,748M | 1,751M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $9.5B | $9.6B | $8.6B | $7.3B | $9.6B | $10.5B | $7.9B | $6.1B | $6.3B | $5.6B | $3.2B | $3.0B | $3.7B | $3.3B | $9.3B | $9.0B | $8.7B | $7.3B | $7.3B | $5.2B | $5.3B |
| Capital Expenditures (CapEx) | $2.1B | $2.2B | $2.2B | $2.2B | $1.8B | $1.9B | $2.2B | $1.6B | $1.4B | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B | $1.8B | $1.5B | $1.0B | $1.1B | $1.3B | $1.7B | $1.3B |
| Free Cash Flow (FCF) | $7.4B | $7.4B | $6.4B | $5.1B | $7.8B | $8.6B | $5.7B | $4.5B | $4.9B | $4.4B | $2.1B | $1.9B | $2.6B | $2.2B | $7.5B | $7.5B | $7.7B | $6.2B | $6.1B | $3.5B | $4.0B |
| FCF Margin % | 16.4% | 16.7% | 15.1% | 12.6% | 17.9% | 20.1% | 16.5% | 14.1% | 16.0% | 16.2% | 10.0% | 9.1% | 12.8% | 10.0% | 18.9% | 19.2% | 21.9% | 20.1% | 20.5% | 13.6% | 17.8% |
| Dividends Paid | $4.2B | $4.1B | $3.8B | $3.6B | $3.3B | $3.2B | $2.6B | $2.3B | $2.0B | $1.8B | $1.5B | $1.4B | $1.3B | $882M | $3.2B | $2.9B | $2.7B | $2.4B | $2.2B | $2.0B | $1.8B |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $1.3B | $3.3B | $2.8B | $2.0B | $1.4B | $2.9B | $2.7B | $2.0B |
| Capital Expenditures (CapEx) | $399M | $689M | $496M | $502M | $484M | $720M | $556M | $533M |
| Free Cash Flow (FCF) | $916M | $2.6B | $2.3B | $1.5B | $933M | $2.1B | $2.1B | $1.4B |
| FCF Margin % | 8.2% | 22.9% | 20.2% | 13.9% | 9.0% | 19.6% | 20.2% | 13.8% |
| Dividends Paid | $1.1B | $1.0B | $1.0B | $1.0B | $1.0B | $958M | $960M | $961M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $110.4B | $86.7B | $81.4B | $73.2B | $74.4B | $75.2B | $72.5B | $67.9B | $67.2B | $76.2B | $55.0B | $44.0B | $43.8B | $43.0B | $67.2B | $60.3B | $60.6B | $52.6B | $42.4B | $39.7B | $36.2B |
| Cash & Cash Equivalents | $6.8B | $8.5B | $7.6B | $6.9B | $9.9B | $9.8B | $6.8B | $3.9B | $3.8B | $9.4B | $18.6B | $5.0B | $4.1B | $3.5B | $10.8B | $6.8B | $7.3B | $8.8B | $4.1B | $2.5B | $521M |
| Total Liabilities | $57.7B | $33.9B | $33.5B | $34.4B | $37.5B | $39.2B | $39.5B | $36.6B | $36.5B | $45.2B | $31.9B | $19.9B | $19.6B | $17.7B | $40.4B | $35.8B | $37.0B | $29.5B | $24.9B | $21.9B | $22.1B |
| Total Debt (Short + Long-Term) | $34.0B | $13.2B | $14.4B | $14.9B | $17.0B | $18.3B | $19.0B | $18.3B | $19.6B | $27.9B | $22.0B | $9.0B | $7.8B | $6.6B | $20.5B | $15.4B | $18.9B | $16.5B | $11.4B | $12.2B | $12.4B |
| Total Shareholders' Equity | $52.1B | $52.1B | $47.7B | $38.6B | $36.7B | $35.8B | $32.8B | $31.1B | $30.5B | $30.9B | $20.5B | $21.2B | $21.5B | $25.2B | $26.7B | $24.4B | $22.7B | $23.1B | $17.5B | $17.8B | $14.1B |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ABT viewer.
About TickerBase · Data methodology & sources